{
    "title": "Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-11966611/Vertex-CRISPRs-gene-editing-therapy-cost-effective-1-9-million--pricing-review-group.html",
    "date": "2023-04-12",
    "keywords": [
        "gene",
        "therapy",
        "disease",
        "scd",
        "crispr",
        "cell",
        "drug",
        "icer",
        "price",
        "sickle",
        "blood",
        "beta",
        "thalassemia",
        "disorder",
        "range",
        "health",
        "account",
        "pricing",
        "group",
        "approval",
        "technology",
        "transfusiondependent",
        "dose",
        "damage",
        "pain",
        "death",
        "draft",
        "report",
        "institute",
        "review",
        "cost",
        "effectiveness",
        "care",
        "system",
        "government",
        "agency",
        "say",
        "access",
        "list",
        "mark",
        "year",
        "drugmaker",
        "csl",
        "ltd",
        "hemophilia",
        "b",
        "record",
        "bluebird",
        "dozen",
        "edge",
        "patient",
        "occurs",
        "control",
        "prevention",
        "sangamo",
        "vertex",
        "reporting",
        "mahobe",
        "roy",
        "bengaluru",
        "editing",
        "shinjini",
        "ganguli",
        "sonali",
        "paul"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}